Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias

Autor(es)

Marchioni, Camila ^[1] ; Santos-Lobato, Bruno Lopes ^{[2, 3]} ; Costa Queiroz, Maria Eugenia ^{[1, 4]} ; Crippa, Jose Alexandre S. ^[2] ; Tumas, Vitor ^[2]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Ribeirao Preto - Brazil

^[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Neurosci & Behav, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP - Brazil

^[3] Fed Univ Para, Inst Hlth Sci, Belem, Para - Brazil

^[4] Univ Sao Paulo, Chem Dept, Ribeirao Preto - Brazil

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF NEURAL TRANSMISSION; v. 127, n. 10 AUG 2020.
• Citações Web of Science: 0

Resumo

Levodopa-induced dyskinesias (LID) in Parkinson's disease (PD) are frequent complications, and the endocannabinoid system has a role on its pathophysiology. To test the hypothesis that the functioning of the endocannabinoid system would be altered in PD and in LID by measuring plasma and CSF levels of alpha-N-arachidonoylethanolamine (AEA) and 2-arachidonoyl-glycerol (2-AG) in patients with PD with and without LID and in healthy controls. Blood and CSF samples were collected from 20 healthy controls, 23 patients with PD without LID, and 24 patients with PD with LID. The levels of AEA and 2-AG were measured using a highly sensitive column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method. When pooled together, patients with PD had lower plasma and CSF levels of 2-AG and higher CSF levels of AEA compared to healthy controls (Mann-Whitney statistics = 303.0,p = 0.02). Patients with PD without LID had lower CSF levels of 2-AG (Kruskal-Wallis statistics = 7.76,p = 0.02) and higher CSF levels of AEA levels than healthy controls (Kruskal-Wallis statistics = 8.81,p = 0.01). The findings suggest that the endocannabinoid system participates in the pathophysiology of PD symptoms, but its role in the pathophysiology of LID is still unclear. (AU)

• Processo FAPESP: 12/17626-7 - Mecanismos celulares e moleculares envolvidos no papel de neurotransmissores atípicos em transtornos neuropsiquiátricos
• Beneficiário: Francisco Silveira Guimaraes
• Linha de fomento: Auxílio à Pesquisa - Temático